Kodiak Sciences to Present at Three Upcoming Investor Conferences
Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth will present at three investor conferences in November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth will present at three investor conferences in November and December 2026.
He will speak at the Jefferies Global Healthcare Conference on November 16 and the UBS Global Biopharma Conference on November 17, both in London, and the 9th Annual Evercore Healthcare Conference on December 1 in Miami. Live webcasts and limited-time replays will be available on Kodiak's investor relations website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Jefferies Global Healthcare Conference
Monday, November 16, 2026
12:30 – 12:55 PM GMTLondon, UK - UBS Global Biopharma Conference
Tuesday, November 17, 2026
9:20 – 9:50 AM GMTLondon, UK - 9th Annual Evercore Healthcare Conference
Tuesday, December 1, 2026
7:55 – 8:15 AM ETMiami, FL
Live webcasts of the presentations will be available in the "Events and Presentations" section of Kodiak's investor relations website at http://ir.kodiak.com/. Replays will be available for a limited time following each presentation.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in wet age-related macular degeneration (wet AMD), diabetic retinopathy and retinal vein occlusion. KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the timing of topline data readouts from the PEAK and PINNACLE Phase 3 studies. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's Annual Report on Form 10-K for the year ended December 31, 2025 as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.
Kodiak®, Kodiak Sciences® and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-three-upcoming-investor-conferences-302937051.html
SOURCE Kodiak Sciences Inc.